Liver transplant patients: how often does muscle weakness linger?

NCT ID NCT05216991

Completed Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study from Mayo Clinic looked at 97 liver transplant patients to see how often they had lasting muscle weakness after surgery when given sugammadex, a drug to reverse anesthesia. Researchers used a device called TetraGraph to measure muscle response. The goal was to estimate the frequency of residual weakness and its impact on recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sugammadex
What this could lead to: If successful, this could help doctors better manage anesthesia recovery in liver transplant patients, reducing complications from muscle weakness.
What could go wrong: This is a small, completed observational study, not a treatment trial. Results may not apply to all patients or change standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER TRANSPLANT SURGERY

Contacts and locations

Locations

Mayo Clinic Florida

Jacksonville, Florida, 32224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.